Key result
Lower serum adiponectin is linked to increased cancer malignancy, suggesting a role in tumorigenesis.
Why the study?
Lower serum adiponectin levels are associated with increased malignancy in various cancers, but the exact role of adiponectin in cancer diagnosis and therapy remains unclear.
Answers are grounded in this paper and cite their sources.
Serum adiponectin levels and downstream signaling targets may serve as potential diagnostic markers for malignancies.
Adiponectin (APN), a novel hormone/cytokine derived from adipocyte tissue, is involved in various physiological functions. Genetics, nutrition, and adiposity are factors contributing to circulating plasma concentrations of APN. Clinical correlation studies have shown that lower levels of serum APN are associated with increased malignancy of various cancers, such as breast and colon cancers, suggesting that APN has a role in tumorigenesis. APN affects insulin resistance, thus further influencing cancer development. Tumor cells may express receptors for APN. Cellular signaling is the mechanism by which APN exerts its host-protective responses. These factors suggest that serum APN levels and downstream signaling targets of APN may serve as potential diagnostic markers for malignancies. Further research is necessary to clarify the exact role of APN in cancer diagnosis and therapy.
No takes yet. Share an insight, caveat, or question.
Obeid et al. (2012) conducted a review in Cancer. Adiponectin (APN) was evaluated. Lower levels of serum adiponectin are associated with increased malignancy of various cancers, such as breast and colon cancers, suggesting a role in tumorigenesis.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: